U.S. Markets closed

BioNovelus, Inc. Moving to Fully Reporting Status With SEC

SCOTTSDALE, AZ / ACCESSWIRE / June 17, 2016 / BioNovelus, Inc. (ONOV) is pleased to announce that it is taking steps to become a fully reporting company in order in the future to be able to uplist its shares and move to more visible marketplaces.

Mr. Jean Ekobo, President/CEO of BioNovelus, Inc., said, "This represents a huge milestone for our Company and its shareholders. It will add a great deal of value for our Company going forward and will enable us to move ahead in regards to attracting new investment and funding our future production."

BioNovelus has retained the Law firm of Ryley Carlock & Applewhite to achieve this 8-k process.

Business Insider said, "After crude oil, coffee is the most sought commodity in the world. Coffee is worth over $100 billion worldwide annually. That puts it ahead of commodities like natural gas, gold, brent oil, sugar and corn."

Coffee rust, a fungus devastating coffee plantations, has cost over $2.5 B between 2012 and 2015 (Source: ICafé) in Central America only. BioNovelus bio-fungicide CR-10 has been tested with great success for four months in five farms by CoopeAgri, one of the major Costa Rican cooperatives. Recently, CoopeTarrazu and Aquiares, respectively serving Starbucks and Nestle (with Nespresso), have joined the movement, and are starting to put CR-10 to the test. Results for these new pilot tests are expected in two to three months.

Concurrently, ICafé, the Coffee Trade Association in Costa Rica, is testing biodegradable CR-10 in its laboratory in order to give its seal of approval to the coffee growers.

About BioNovelus Inc.

BioNovelus, Inc. (ONOV) is a biotech company that honors the environment with an innovative, cost effective, and disruptive technology-based solution to the problems of safety and cleanliness regarding food production and water supply.

Additional Information

For additional information: http://bionovelus.com

Please contact: Nathalie Ekobo,
Marketing & Communications Director
BioNovelus, Inc.:

Skype: bionovelus.inc
+1 602-888-3424

Forward-Looking Statements

This news release includes forward-looking statements covered by the Private Securities Litigation Reform Act of 1995. Because such statements deal with future events, they are subject to various risks and uncertainties and actual results for fiscal year 2015 and beyond could differ materially from the Company's current expectations. Forward-looking statements are identified by words such as "anticipates," "projects," "expects," "plans," "intends," "believes," "estimates," "targets," and other similar expressions that indicate trends and future events.

Factors that could cause the Company's results to differ materially from those expressed in forward-looking statements include, without limitation, variation in demand and acceptance of the Company's products and services, the frequency, magnitude and timing of paper and other raw-material-price changes, general business and economic conditions beyond the Company's control, timing of the completion and integration of acquisitions, the consequences of competitive factors in the marketplace including the ability to attract and retain customers, results of continuous improvement and other cost-containment strategies, and the Company's success in attracting and retaining key personnel. The Company undertakes no obligation to revise or update forward-looking statements as a result of new information, since these statements may no longer be accurate or timely.

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933, and are subject to Rule 3B-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this press release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and other results and further events could differ materially from those anticipated in such statements. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.

SOURCE: BioNovelus Inc.